Sales of major proton pump inhibitor (PPI) class of antiulcer drugs showed mixed performance last year. ‘Nexium (esomeprazole)’ saw a 4% year-on-year decline in prescriptions, while ‘Lanston LFDT (lansoprazole)’ and ‘Pariet (rabeprazole)’ also saw a decline in prescriptions.

Hanmi Pharmaceutical's ‘Esomezol (esomeprazole)’ and Ilyang Pharmaceutical's ‘Noltec (ilaprazole)’ saw an increase in prescriptions last year. However, the increase has slowed down recently. This may be due to the rapid growth of its competitors such as P-CABs (potassium-competitive acid blockers).

Presciptions of Esomezol·Esomezol Plus rise 3% in 1 yr…sales growth slows down